Immunocore Holdings plc

Healthcare · Biotechnology · United Kingdom

Last price 30.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.57B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ...